Klein to stay on as CIRM chair for six months; PregLem, Watson strike marketing pact; Regligen gains research grant

@FierceBiotech: Want the next blockbuster drug? It's all in the delivery. Report | Follow @FierceBiotech 

 @JohnCFierce: Playing catch-up, the FDA issues guidelines on developing new combo drugs. Report | Follow @JohnCFierce

> Bob Klein says he will stay on as an unpaid chairman of California's stem cell program for an additional six months as officials continue looking for someone to head up the controversial project. Report

> PregLem has struck a deal with Watson Pharmaceuticals on the development and marketing of Esmya, a late-stage program for uterine fibroids (myoma). Story

> Repligen won a $1.4 million grant from the Muscular Dystrophy Association to funds work on a new therapy for spinal muscular atrophy. Report

> Myotec Therapeutics and Hybrid BioSystems announced their merger to form PsiOxus Therapeutics, a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus will be led by CEO Dr. John Beadle. Myotec release 

> Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialization agreement which Boehringer signed in November, 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo two years later. Orexo release

And Finally... The performance of a brain-machine interface designed to help paralyzed subjects move objects with their thoughts is improved with the addition of a robotic arm providing sensory feedback, a new study from the University of Chicago finds. Release

Suggested Articles

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.

The treatment staved off cancer for a median of 16.4 months and shrank tumors in 61% of patients with HER2-positive breast cancer.